abstract |
Methods and systems to reduce neurotoxicity associated with the treatment of CD19+ B-cell hyperproliferative disorders are disclosed. Neurotoxicity is reduced by the use of agents that protect CD19+ neurovascular pericytes and/or CD19+ vSMCs from attack by CD19-targeted therapy, and by modification of CD19-targeted therapy to avoid CD19+ pericytes and/or CD19+ vSMCs. |